A Phase 2 interventional study of Slit Lamp Examination and Far Best Corrected Visual Acuity (BCVA) in Moderate to Severe Vernal Keratoconjunctivitis, sponsored by Laboratoires Thea. Recruiting at 11 sites in India. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Laboratoires Thea · Phase 2, Interventional, and Treatment
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
210 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
This study's planned enrollment of 120 is above the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Browse Conjunctivitis, Allergic studies →Laboratoires Thea is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Participants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participant should instill T1695.
Diagnostic Test: Slit Lamp Examination · Diagnostic Test: Far Best Corrected Visual Acuity (BCVA) · Drug: T1695 · Diagnostic Test: Corneal fluorescein staining score on modified Oxford scale
The participant should instill Ciclosporin.
Diagnostic Test: Slit Lamp Examination · Diagnostic Test: Far Best Corrected Visual Acuity (BCVA) · Drug: Ciclosporin · Diagnostic Test: Corneal fluorescein staining score on modified Oxford scale
The participant will have a slit lamp examination
The participant 's BCVA will be evaluated.
The participant should instill T1695.
The participant should instill Ciclosporin.
One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
Change from baseline (Day 1) at Day 29 (Week 4) in Corneal Fluorescein Staining (CFS) grade assessed by the (0-5) modified Oxford scale in the study eye.
Time frame: From Day 1 to Day 29
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.